Hims & Hers Health, Inc. (HIMS)
Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)
Hims & Hers Health stock has surged 212% since my previous “buy” rating. Despite strong revenue and earnings growth expectations, I recommend holding off at the moment. Hims & Hers has consistently beat its revenue and earnings for the past several quarters, while the management has raised their forward expectations as a result of their Personalized solutions. However, the latest surge in the stock price is attributed to its provocative Super Bowl ad and favorable outlook on the regulatory landscape after RFK Jr.'s appointment as the Health Secretary.
Hims & Hers Earnings Could Be a Game Changer—What to Do Now
There are a few stocks that come along every once in a while, arriving to change the way an old-fashioned industry works and operates. When investors get lucky enough to find one of them, it can typically bring on life-changing returns, even retiring them from active work if they choose to go that route.
Hims & Hers Stock Is On Fire, But Is It a Bubble?
Shares of Hims & Hers (HIMS -0.96%) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the company's high short interest in this video.
What Is Driving Hims & Hers Stock Higher?
In this video, I will talk about recent updates regarding Hims & Hers Health (HIMS -1.85%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Hims & Hers Stock Jumps 156.9% in Three Months: What's Next?
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
Hims & Hers: From Viral Ad to Volatile Stock
Hims & Hers Health's NYSE: HIMS share price has surged recently, climbing above $60 and creating new 52-week and all-time record highs for the company. This significant increase in Hims & Hers Health's stock price has attracted considerable attention from investors.
Hims & Hers Health Stock: A Millionaire-Maker in the Making?
Shares of direct-to-consumer telehealth platform Hims & Hers Health (HIMS 2.18%) have become a runaway freight train. The stock has returned nearly 20-fold returns from its 2022 lows, including a blistering 490% over the past year alone.
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $60.30, signifying a +1.88% move from its prior day's close.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Buy, Sell, Or Hold HIMS Stock At $60?
The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has surged an impressive 43% over the past week. A major driver of this growth was the company's widely discussed Super Bowl commercial, which aired on Sunday.
Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Hims & Hers Terrifies Big Pharma
Hims & Hers (HIMS 1.82%) launched a Super Bowl ad this week, and everyone from pharmaceutical companies to pharmacists tried to block it. Travis Hoium explains why that's a great sign that the company's disruptive potential is real.
